Sort
15,273 grants matching “antimicrobial resistance”
Control of mucosal immunity by Gas- vs Gai-linked GPCR signaling in dendritic cells
$461,125Eyal Raz · University Of California, San Diego · U01 · FY2017 · AI
Human GBPs in cell-autonomous immunity to intracellular bacterial pathogens
$461,069Joern Coers · Duke University · R01 · FY2020 · AI
The Discovery of New Antibiotics from Deep Sea Actinomycete Bacteria
$460,799William Fenical · University Of California, San Diego · R01 · FY2010 · GM
Binding and regulation mechanism for S aureus
$460,519Dartmouth College · R01 · FY2002 · AI
Interleukin-1 cytokines in regulating corneal innate immunity against microbial infection
$460,498Fu-Shin X Yu · Wayne State University · R01 · FY2017 · EY
Parallel phenotyping to dissect genetic determinants of bacterial strain diversity
$460,303Allison Carey · University Of Utah · DP2 · FY2023 · AI
Repurposing auranofin and ebselen for treatment of multidrug resistant pathogens
$460,295Mohamed Seleem · Virginia Polytechnic Inst And St Univ · R01 · FY2021 · AI
A Novel Screen for Antibacterials that Are Non-Toxic to Mammals
$460,280Corrella Detweiler · University Of Colorado · R33 · FY2019 · AI
Role of tyrosine kinases in EPEC and EHEC pathogenesis
$460,091Daniel Kalman · Emory University · R01 · FY2006 · AI
O-GlcNAc:Developing New Tool for Assessment of Glycemia
$460,067Gerald Warren Hart · Johns Hopkins University · R33 · FY2008 · DK
Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States
$460,033Reza Yaesoubi · Yale University · R01 · FY2020 · AI
Site Development for Emerging Diseases and Biodefense
$460,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2013 · AI
Control of Transcription Initiation
$459,883Deborah M Hinton · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2023 · DK
Mucosal immunity to Toxoplasma gondii
$459,876Felix Yarovinsky · University Of Rochester · R01 · FY2021 · AI
Mucosal immunity to Toxoplasma gondii
$459,876Felix Yarovinsky · University Of Rochester · R01 · FY2020 · AI
Mucosal immunity to Toxoplasma gondii
$459,876Felix Yarovinsky · University Of Rochester · R01 · FY2022 · AI
Mucosal immunity to Toxoplasma gondii
$459,876Felix Yarovinsky · University Of Rochester · R01 · FY2019 · AI
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
$459,825Michaela Ulrike Gack · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · AI
The Role of TRIM23 in Autophagy Mediated Antiviral Defenses
$459,825Michaela Ulrike Gack · Cleveland Clinic Lerner Com-Cwru · R01 · FY2024 · AI
A synergy-based therapy against C. difficile
$459,800Kim Lewis · Northeastern University · R01 · FY2010 · AI
THE EMERGENCE OF ANTIBIOTIC RESISTANT MICROORGANISMS (ARMS) HAS CONTINUED TO LIMIT THE EFFECTIVENESS OF ANTIBIOTIC THERAPY OF INFECTED HUMANS AND ANIMALS. DESPITE THE GROWING NEGATIVE IMPACT OF ANTIMICROBIAL RESISTANCE (AR) ON PUBLIC AND ANIMAL HEALTH THERE ARE A FEW EFFECTIVE STRATEGIES FOR REDUCING THEIR PREVALENCE IN FARM ANIMALS. IN THIS STUDY WE PROPOSE TO DEVELOP AN INTEGRATED TECHNOLOGY TO MITIGATE THE PROBLEMS CASED BY ARMS. WE WILL 1) DEVELOP INNOVATIVE APPLICABLE NANO SIZE ANTIMICROBIALS BY COMBINING CHITOSAN NANOPARTICLES ANTIBIOTICS AND Β-LACTAMASE (AN ENZYME THAT BREAK DOWN ANTIBITOTICS) INHIBITORS (CNAI) 2) ELUCIDATE MECHANISMS OF ANTIMICROBIAL ACTIVITY DRUG DELEVERY/RELEASE AND POTENTIAL SIDE EFFECTS AND 3) EVALUATE EFFICACY OF DEVELOPED ANTIMICROBIALS IN DAIRY COWS INFECTED WITH MULTI-DRUG RESISTANT BACTERIA TO TREAT METRITIS DISEASE. METRITIS IS AN ACUTE INFLAMMATORY DISEASE OF THE UTERINE LINING CAUSED BY MICROBIAL INFECTION WITH SYSTEMIC IMPLICATIONS THAT AFFECTS 20 TO 40% OF DAIRY COWS AFTER CALVING. THE DIRECT ECONOMIC COST TO THE US DAIRY INDUSTRY ASSOCIATED WITH METRITIS IS APPROXIMATELY $600 MILLION ANNUALLY. THIS PROPOSED WORK IS INNOVATIVE AND SIGNIFICANT BECAUSE OUTCOMES OF THIS PROJECT ARE EXPECTED TO LEAD TO PRACTICAL EFFECTIVE NEW TREATMENT OPTIONS USING NANOTECHNOLOGY. OVERALL WE EXPECT THAT THE DEVELOPMENT OF THE NEW HIGH VALUE-ADDED NANO-ANTIMICROBIALS WILL HELP IMPROVE ANIMAL AND HUMAN HEALTH. FURTHERMORE THE STUDY WILL BE A FRAMEWORK TO TREAT INFECTIONS CAUSED BY MULTI-DRUG RESISTANT PATHOGENS ON PUBLIC AND ANIMAL HEALTH.
$459,775University Of Florida · · FY2019 · National Institute of Food and Agriculture
Precision coordination of therapeutic and prophylactic antibiotics to reduce infection, toxicity, and emergence of resistance following acute abdominal surgery
$459,656Manjunath P Pai · University Of Michigan At Ann Arbor · R01 · FY2024 · HS
Infectious Diseases and Microbial Immunology Post-doctoral Training Program
$459,624Thomas H Kawula · Washington State University · T32 · FY2023 · AI
Hydrolysis-resistant resin networks for durable and multifunctional dental restorations
$459,595Jirun Sun · Ada Forsyth Institute, Inc. · R01 · FY2025 · DE
Biologically Active Cyclic Peptides
$459,563Dale L Boger · Scripps Research Institute, The · R01 · FY2023 · CA